CAPR vs. ALIM, GLSI, ME, GOSS, TRVI, VERU, VACC, ATOS, ACET, and OGI
Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Alimera Sciences (ALIM), Greenwich LifeSciences (GLSI), 23andMe (ME), Gossamer Bio (GOSS), Trevi Therapeutics (TRVI), Veru (VERU), Vaccitech (VACC), Atossa Therapeutics (ATOS), Adicet Bio (ACET), and Organigram (OGI). These companies are all part of the "pharmaceutical preparations" industry.
Capricor Therapeutics (NASDAQ:CAPR) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.
In the previous week, Capricor Therapeutics had 7 more articles in the media than Alimera Sciences. MarketBeat recorded 9 mentions for Capricor Therapeutics and 2 mentions for Alimera Sciences. Capricor Therapeutics' average media sentiment score of 0.30 beat Alimera Sciences' score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the media.
Alimera Sciences received 14 more outperform votes than Capricor Therapeutics when rated by MarketBeat users. However, 62.57% of users gave Capricor Therapeutics an outperform vote while only 57.72% of users gave Alimera Sciences an outperform vote.
21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 99.8% of Alimera Sciences shares are owned by institutional investors. 12.0% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 31.4% of Alimera Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Capricor Therapeutics currently has a consensus price target of $24.00, suggesting a potential upside of 343.62%. Alimera Sciences has a consensus price target of $7.50, suggesting a potential upside of 114.90%. Given Capricor Therapeutics' higher probable upside, analysts clearly believe Capricor Therapeutics is more favorable than Alimera Sciences.
Capricor Therapeutics has a beta of 3.99, meaning that its share price is 299% more volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.
Alimera Sciences has a net margin of -24.93% compared to Capricor Therapeutics' net margin of -88.52%. Alimera Sciences' return on equity of -130.90% beat Capricor Therapeutics' return on equity.
Alimera Sciences has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Alimera Sciences beats Capricor Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Capricor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capricor Therapeutics Competitors List
Related Companies and Tools
